Literature DB >> 12720524

Pharmacological approaches to the management of schizophrenia.

Timothy J R Lambert1, David J Castle.   

Abstract

Pharmacological treatment remains the mainstay of the management of schizophrenia. Older, "typical" antipsychotics carry a significant burden of side effects, notably extrapyramidal and neurocognitive side effects. Newer, "atypical" agents carry a lower risk of extrapyramidal side effects. They appear to have added benefit for treating negative and cognitive symptoms of schizophrenia, and hence can enhance the quality of life of some patients. The choice of particular agents for individual patients requires a balancing of efficacy and side effects. Medication is only one element of what should be an individualised comprehensive treatment plan for people with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12720524     DOI: 10.5694/j.1326-5377.2003.tb05309.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  3 in total

1.  In vitro and in vivo demonstration of risperidone implants in mice.

Authors:  C Rabin; Y Liang; R S Ehrlichman; A Budhian; K L Metzger; C Majewski-Tiedeken; K I Winey; S J Siegel
Journal:  Schizophr Res       Date:  2007-08-31       Impact factor: 4.939

2.  Risperidone long-acting injection in the treatment of schizophrenia spectrum illnesses: A retrospective chart review of 19 patients in the Vancouver Community Mental Health Organization (Vancouver, Canada).

Authors:  Soma Ganesan; Mario McKenna; Ric M Procyshyn; Sheldon Zipursky
Journal:  Curr Ther Res Clin Exp       Date:  2007-11

3.  Analyzing the influence of BDNF heterozygosity on spatial memory response to 17β-estradiol.

Authors:  Y W C Wu; X Du; M van den Buuse; R A Hill
Journal:  Transl Psychiatry       Date:  2015-01-20       Impact factor: 6.222

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.